April 19th 2024
The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.
Top New Cardiometabolic Health Guidelines/Recommendations in 2022
December 28th 2022Our recap of new guidelines and recommendations related to diabetes management from 2022 includes the 2023 Standards of Care, USPSTF recommendation on type 2 diabetes screenings in adolescents, recommendations for pharmacologic management of obesity, new bariatric surgery guidance, and a consensus report on use of automated insulin delivery.
Diabetes Dialogue: 2022 Year in Review
December 27th 2022To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.
Endocrine Month in Review: December 2022
December 24th 2022The last full weekend of each month, our editorial team compiles a list of our most popular endocrinology content from the past month for a month in review recap. The December 2022 endocrinology month in review features coverage of the FDA’s clearance of Dexcom G7, new data related to use of SGLT2 inhibitors in pediatric type 2 diabetes, and the ADA's Standards of Care in Diabetes—2023.
Diabetes Dialogue: December 2022
December 23rd 2022In the December 2022 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.
Mediterranean Diet Linked to Reduce Risk of Adverse Pregnancy Outcomes in Nulliparous Women
December 23rd 2022Data from the nuMoM2b study suggests greater adherence to a Mediterranean diet was associated with reductions of 37%, 28%, and 21% in odds of gestational diabetes, preeclampsia, and any adverse pregnancy outcome, respectively, among a cohort of more than 7000 nulliparous women.
Diabetes Dialogue: The Psychology of Diabetes Management, with Jill Weissberg-Benchell, PhD
December 22nd 2022In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.
Diabetes Dialogue: The History and Future of Diabetes Technology, with Richard Bergenstal, MD
December 21st 2022In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.
Despite Advances, Decades-Old Racial Disparities Persist in Glycemic Control in the US
December 20th 2022An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.
Study Details Rates of Glycemic Emergencies Among Medicare Beneficiaries from 2011-2020
December 16th 2022Using data from Medicare Advantage beneficiaries from 2011-2020, investigators provide an overview of trends of severe hyperglycemic- and hypoglycemic-related hospitalizations and emergency department visits among those with type 1 or type 2 diabetes.
Diabetes Dialogue: Updates in Inpatient Management of Diabetes, with Jane Jeffrie Seley, DNP, MPH
December 13th 2022In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.
Empagliflozin Proves Benefit in Pediatric Type 2 Diabetes in Phase 3 DINAMO Trial
December 7th 2022Eli Lilly and Company and Boehringer Ingelheim announced their SGLT2 inhibitor, empagliflozin, was associated with statistically significant reductions in HbA1c relative to placebo therapy among a population of pediatric patients with type 2 diabetes in the DINAMO trial.